JP4658940B2 - 第Xa因子阻害剤としてのベンゾイミダゾール誘導体 - Google Patents

第Xa因子阻害剤としてのベンゾイミダゾール誘導体 Download PDF

Info

Publication number
JP4658940B2
JP4658940B2 JP2006529739A JP2006529739A JP4658940B2 JP 4658940 B2 JP4658940 B2 JP 4658940B2 JP 2006529739 A JP2006529739 A JP 2006529739A JP 2006529739 A JP2006529739 A JP 2006529739A JP 4658940 B2 JP4658940 B2 JP 4658940B2
Authority
JP
Japan
Prior art keywords
chloro
benzimidazole
ylcarbamoyl
carboxylic acid
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006529739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528213A (ja
JP2006528213A5 (enExample
Inventor
マルク・ナザレ
ミヒャエル・ヴァーグナー
フォルクマール・ヴェーナー
ハンス・マター
マティーアス・ウーアマン
クルト・リッター
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33040952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4658940(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006528213A publication Critical patent/JP2006528213A/ja
Publication of JP2006528213A5 publication Critical patent/JP2006528213A5/ja
Application granted granted Critical
Publication of JP4658940B2 publication Critical patent/JP4658940B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2006529739A 2003-05-19 2004-05-05 第Xa因子阻害剤としてのベンゾイミダゾール誘導体 Expired - Fee Related JP4658940B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011305A EP1479676A1 (en) 2003-05-19 2003-05-19 Benzimidazole-derivatives as factor xa inhibitors
PCT/EP2004/004750 WO2004101553A1 (en) 2003-05-19 2004-05-05 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (3)

Publication Number Publication Date
JP2006528213A JP2006528213A (ja) 2006-12-14
JP2006528213A5 JP2006528213A5 (enExample) 2007-05-24
JP4658940B2 true JP4658940B2 (ja) 2011-03-23

Family

ID=33040952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529739A Expired - Fee Related JP4658940B2 (ja) 2003-05-19 2004-05-05 第Xa因子阻害剤としてのベンゾイミダゾール誘導体

Country Status (29)

Country Link
EP (2) EP1479676A1 (enExample)
JP (1) JP4658940B2 (enExample)
KR (1) KR20060014056A (enExample)
CN (2) CN101139346A (enExample)
AR (1) AR045683A1 (enExample)
AT (1) ATE474838T1 (enExample)
AU (1) AU2004238497B2 (enExample)
BR (1) BRPI0410446A (enExample)
CA (1) CA2526065A1 (enExample)
CL (1) CL2004001078A1 (enExample)
CR (1) CR8087A (enExample)
DE (1) DE602004028240D1 (enExample)
EC (1) ECSP056178A (enExample)
MA (1) MA27798A1 (enExample)
MX (1) MXPA05012231A (enExample)
NO (1) NO20055910L (enExample)
NZ (1) NZ543670A (enExample)
OA (1) OA13168A (enExample)
PA (1) PA8603501A1 (enExample)
PE (1) PE20050198A1 (enExample)
RS (1) RS20050856A (enExample)
RU (1) RU2346944C2 (enExample)
SA (1) SA04250196B1 (enExample)
TN (1) TNSN05297A1 (enExample)
TW (1) TW200503696A (enExample)
UA (1) UA82100C2 (enExample)
UY (1) UY28324A1 (enExample)
WO (1) WO2004101553A1 (enExample)
ZA (1) ZA200508151B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377642A (en) * 1971-01-14 1974-12-18 Koninklijke Gist Spiritus Penicillanic and cephalosporanic acid derivatives
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
DE3828537A1 (de) * 1988-08-23 1990-03-01 Basf Ag Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material
JPH0324609A (ja) * 1989-06-21 1991-02-01 Mitsuba Electric Mfg Co Ltd I/o用バッファic
JPH03184043A (ja) * 1989-12-14 1991-08-12 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
KR100190299B1 (ko) * 1990-07-19 1999-06-01 디르크 반테 신규한 옥사졸릴 유도체
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SI9520096A (sl) * 1994-09-30 1998-04-30 Pfizer Inc. Derivati 2,7-substituiranega oktahidro-1H-pirido /1,2-a/ pirazina
JPH08208640A (ja) * 1995-02-06 1996-08-13 Nisshin Flour Milling Co Ltd ベンズイミダゾール誘導体およびそれを含有する心不全治療薬
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH09124609A (ja) * 1995-11-07 1997-05-13 Nissan Chem Ind Ltd ベンズイミダゾール誘導体
JPH10182459A (ja) * 1996-12-26 1998-07-07 Otsuka Pharmaceut Co Ltd cGMP分解酵素阻害剤
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
TR200002904T2 (tr) * 1998-04-10 2001-02-21 Japan Tobacco Inc. Amidin bileşikleri
RS20050201A (sr) * 2002-09-06 2007-06-04 Janssen Pharmaceutica N.V., Heterociklična jedinjenja

Also Published As

Publication number Publication date
RU2005139555A (ru) 2006-06-10
UA82100C2 (uk) 2008-03-11
NZ543670A (en) 2008-09-26
JP2006528213A (ja) 2006-12-14
BRPI0410446A (pt) 2006-06-06
OA13168A (en) 2006-12-13
PE20050198A1 (es) 2005-04-25
MXPA05012231A (es) 2006-08-18
TW200503696A (en) 2005-02-01
DE602004028240D1 (de) 2010-09-02
CN101139346A (zh) 2008-03-12
AU2004238497B2 (en) 2010-07-22
EP1636216B1 (en) 2010-07-21
CR8087A (es) 2006-09-22
ZA200508151B (en) 2007-02-28
SA04250196B1 (ar) 2008-11-18
RU2346944C2 (ru) 2009-02-20
MA27798A1 (fr) 2006-03-01
WO2004101553A1 (en) 2004-11-25
ATE474838T1 (de) 2010-08-15
KR20060014056A (ko) 2006-02-14
AR045683A1 (es) 2005-11-09
WO2004101553B1 (en) 2005-03-03
TNSN05297A1 (en) 2007-07-10
UY28324A1 (es) 2004-12-31
HK1089174A1 (zh) 2006-11-24
CN100484935C (zh) 2009-05-06
CA2526065A1 (en) 2004-11-25
EP1636216A1 (en) 2006-03-22
AU2004238497A1 (en) 2004-11-25
EP1479676A1 (en) 2004-11-24
RS20050856A (sr) 2007-11-15
CL2004001078A1 (es) 2005-04-08
ECSP056178A (es) 2006-08-30
NO20055910L (no) 2006-02-10
PA8603501A1 (es) 2004-11-26
CN1791598A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
JP4709763B2 (ja) 第Xa因子阻害剤としてのインダゾール誘導体
JP4676960B2 (ja) 第Xa因子阻害剤としてのインドール誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
KR20060136457A (ko) 인자 Xa 억제제로서의 피롤-유도체
JP4608495B2 (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
AU2003285336B2 (en) Imidazole-derivatives as factor Xa inhibitors
JP4733642B2 (ja) 第Xa因子阻害剤としてのアザインドール−誘導体
EP1479678A1 (en) Pyrazole-derivatives as factor xa inhibitors
HK1089174B (en) Benzimidazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101224

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees